US biotech Iovance Biotherapeutics (Nasdaq: IOVA) saw its shares drop more than 20% on Tuesday, after it revealed a setback with its clinical program for LN-145 TIL therapy in non-small lung cancer (NSCLC), but jumped back 18.7% to $8.58 on Thursday. Iovance said that the US Food and Drug Administration (FDA) has placed a clinical hold on the IOV-LUN-202 trial, in response to a recently reported Grade 5 (fatal) serious adverse event potentially related…